Steven Gubin, MD
Cardiovascular Disease · Memphis, TNNPI 1497847867
Payments from drug & device makers
Across 1,189 payments — averaging $208.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$55K
- Amgen$46K
- Johnson & Johnson$38K
- AstraZeneca$23K
- Esperion Therapeutics, Inc.$21K
- Sanofi-aventis U.S. LLC$17K
- plus $48K from 45 others
What the payments were for
- Consulting fees$2,0251%
- Speaking & faculty fees$212,61986%
- Travel & lodging$7,0713%
- Food & beverage$25,32010%
- Education$5000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$68,268
- Repatha$43,040
- XARELTO$36,409
- FARXIGA$22,055
- NEXLIZET$19,997
- NEXLETOL$19,997
- PRALUENT$17,686
- OPTIMIZER$11,273
- Inpefa$6,278
- ELIQUIS$2,625
- COBALT DR MRI SURESCAN$528
- Micra$417
- Watchman$339
- ENROUTE Transcarotid Neuroprotection System$221
- VYNDAQEL$219
- BRILINTA$217
- TEGSEDI$214
- WATCHMAN Access System$148
- Barostim Neo System$144
- AMVIA EDGE$144
How this compares
$247,534 in reported general payments places this provider in the 90th percentile of 429 cardiovascular disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 829 | $832,683 |
| Repatha SureclickEvolocumab | 222 | $218,472 |
| XareltoRivaroxaban | 219 | $210,887 |
| EntrestoSacubitril/Valsartan | 130 | $141,674 |
| FarxigaDapagliflozin Propanediol | 153 | $131,160 |
| JardianceEmpagliflozin | 115 | $116,521 |
| Praluent PenAlirocumab | 62 | $41,225 |
| Ezetimibe | 996 | $26,871 |
| Rosuvastatin Calcium | 1,656 | $22,294 |
| BrilintaTicagrelor | 22 | $22,134 |
| Metoprolol Succinate | 1,088 | $18,113 |
| LivaloPitavastatin Calcium | 26 | $17,085 |
| Ranolazine ErRanolazine | 106 | $14,458 |
| VerquvoVericiguat | 13 | $14,089 |
| Nebivolol Hcl | 230 | $13,939 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $3,554 | $832,683829 claims |
| Johnson & JohnsonXarelto | $37,731 | $210,887219 claims |
| AstraZenecaFarxiga, Brilinta | $23,010 | $153,294175 claims |
| NovartisEntresto | $1,823 | $141,674130 claims |
| Boehringer IngelheimJardiance | $54,753 | $116,521115 claims |
| Kowa Pharmaceuticals America, Inc.Livalo, Bystolic | $45 | $22,95545 claims |
| MerckVerquvo | $726 | $14,08913 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $69 | $11,69331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 429 cardiovascular disease providers in Tennessee.
Other cardiovascular disease in Memphis
- Frank McGrewMemphis$2.1M
- Kodangudi RamanathanMemphis$203K
- Adedayo AdeboyeMemphis$129K
- Kishore ArcotMemphis$124K
- Isaac RheaMemphis$75K
- Brian LindmanNashville$5.5M
- David MetzgerKingsport$4.8M
- Christopher EllisNashville$4.1M
- Dinesh GuptaNashville$3.2M
- Joann LindenfeldNashville$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.